Other

Kuraray Co., Ltd.

Zeria Pharmaceutical Co., Ltd.

Asai Germanium Research Institute

Yamanouchi Pharmaceutical Company Ltd.

Kirin Brewery Company, Limited

Hiroshi Maeda

Minophagen Pharmaceutical Co., Ltd.

Kayaku Antibiotics Research Co., Ltd.

Natsu Maruyama

Kirin-Seagram Limited

Fujio Suzuki

Nakao Ishida

Makiko Kobayashi

Hiroshi Satoh

Kouhei Miyao

Hidetaka Sasaki

Tatsuya Oda

Toshikatsu Fujii

Ituro Mizutani

Kiichiro Oka

Shohei Tanaka

Tokuichiro Utsunomiya

Hiroatsu Matsumoto

Midori Takeda

Shigemi Iwata

The object of the present invention is to provide the use of glycyrrhizin and its derivatives for inhibition of MCP-1 production. The present invention discloses an MCP-1 production inhibition method and pharmaceutical composition for the same comprising administration of glycyrrhizin and its derivatives in an amount effective for said inhibition to mammals in which migration of monocytes or T lymphocytes is increased, or production of IL-10 is increased, and inhibition of said increase is desired.

Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors

A method for inhibiting replication of HIV, which comprises subjecting HIV-infected cells to a composition (a) comprising as a primary component a polysaccharide derived from a hot aqueous solvent extract of tubercle bacillus.

Method for inhibiting replication of HIV

The present invention relates to a method for treating AIDS, which comprises administering to an HIV-infected patient (a) a composition containing as the primary component a polysaccharide derived from a hot water extract of human-type tubercle bacillus and (b) a nucleoside-type anti-HIV agent. Due to the incorporation of composition (a), the present invention enhances the therapeutic effect of nucleoside-type anti-HIV agents on AIDS.

Method for treating AIDS

A composition for oral administration to cancer patients includes a neocarzinostatin derivative and from 0.1 and 100 ml per mg of the neocarzinostatin derivative of at least one fatty acid glyceride which has from 6 to 20 carbon atoms and which is noniodized. The composition is effective in the treatment of cancer by oral administration, including a solid cancerous tumor.

Neocarzinostatin derivative composition for oral administration

The invention provides a superoxide dismutase derivative of the general formula

Superoxide dismutase derivatives, a method of producing the same and

Therapeutic induction of interferon production in living animal cells is effected by subjecting such cells to the species-specific interferon inducing effect of an organogermanium compound having the formula:

Organogermanium induction of interferon production

KS-2-B was obtained as purified material from the culture of Daedalea dickinsii KSDD 6 (FERM-P No. 3993), Lentinus edodes KSLE 7 (FERM-P No. 3994) or Lentinus edodes KSLE 28 (FERM-P No. 4196). This substance, KS-2-B, is an effective interferon inducing substance.

KS-2-B

KS-substance was obtained as raw material from the cultured mycelium of Daedalea dickinsii KSDD 6 (FERM-P No. 3993), Lentinus edodes KSLE 7 (FERM-P No. 3994) or Lentinus edodes KSLE 28 (FERM-P No. 4196), and by refining this substance a novel substance KS-2-A was obtained. This substance KS-2-A and also the KS-substance as the raw material both enhance the host defense function of the living body.

KS-2-A

Growing community of inventors

Galveston, TX, United States of America

Fujio Suzuki